Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Experimental hematology - 1 Apr 2007

Gaikwad Amos, Nussenzveig Roberto, Liu Enli, Gottshalk Stephen, Chang KoTung, Prchal Josef T

Abstract excerpt

OBJECTIVES: A G>T transversion in a tyrosine kinase JAK2 (V617F) was reported in over 80% of patients with polycythemia vera (PV). Current evidence suggests that JAK2(V617F) somatic mutation is involved in the pathogenesis of PV, as it confers erythropoietin-independent proliferation to erythroid progenitor cells. However, several unanswered questions regarding the essential role of JAK2(V617F) arose as 1) it is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Culture Media

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Primers

Share to Erythroid Precursor Cells

Share to Erythropoietin

Share to Flow Cytometry

Share to Janus Kinase 2

Share to Polycythemia Vera

Source

Open in PubMed Open full text

Identifiers

PMID: 17379069
DOI: 10.1016/j.exphem.2006.12.007
PMCID: PMC1931508

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.PMID 17379069Read ↗

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.Semantic proximity Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraSemantic proximity Read ↗

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaSemantic proximity Read ↗

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.Semantic proximity Read ↗

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.Semantic proximity Read ↗

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.Semantic proximity Read ↗

Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.Semantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.